Predictors of Weight Loss and Weight Gain in Weight Management Patients during the COVID-19 Pandemic

Objective. To examine the associations between patient struggles, health, and weight management changes during the COVID-19 pandemic. Methods. 585 patients attending a publicly funded clinical weight management program responded to an electronic survey. Results. Over half of the patients reported worsened overall health, mental health, physical activity, or diet during the pandemic. Approximately 30% of patients lost ≥3% of their body weight and 21% gained ≥3% of their body weight between March and July of the pandemic. Reports of social isolation was associated with increased odds for weight loss in women (OR = 2.0, 1.2–3.3), while low motivation (OR = 1.9, 1.0–3.7), depression (OR = 2.5, 1.0–6.3), and struggles with carbohydrate intake (OR = 2.1, 1.0–4.3) were associated with weight gain. Cooking more at home/eating less take out was associated with increased likelihood of weight loss (OR = 2.1, 1.1–3.9) and lower odds for weight gain (OR = 0.2, 0.1 to 0.97). Working from home was not associated with weight loss or weight gain ( P > 0.6 ). Conclusion. The COVID-19 pandemic is associated with certain factors that may facilitate weight loss and other factors that promote weight gain. Thus, depending on the patient experience during the pandemic, prevention of weight gain may be more appropriate than weight loss.

The impact of chemosensory dysfunctions on weight loss

Background: The role of chemosensory senses (olfaction, taste, and trigeminal) is crucial, and their dysfunctions profoundly affect the quality of life, potentially impacting eating behaviors. However, it is unclear which chemosensory symptoms could lead to undernutrition. This study aims to investigate which findings in patients' smell and taste workup are predictors of weight loss. Methods: This is a retrospective study based on a validated questionnaire consecutively given to adult patients presented in smell and taste consultations during a 10-year period. Psychophysical tests were used to measure chemosensory function (Sniffin' Sticks, taste powder, and Taste Strips tests). Results: We included 555 patients (307 females) with a median age of 51 years (IQR 23). Among them, 76 (13.7%) reported involuntary weight loss due to chemosensory disorders occurred over periods ranging from 3 to 36 months. We found that the odds of losing weight were 2.1 times higher when patients reported changes in aroma perception (p-value=0.012; 95% CI 1.15 - 3.83). Parosmia, but not phantosmia nor smell loss, was a significant predictor of weight loss (OR 2.22; p-value=0.015; 95% CI 1.17 - 4.2). Furthermore, the duration of symptoms for more than two years was protective for weight loss (OR 0.44; p-value=0.014; 95% CI 0.23 - 0.85). Regarding putative etiologies, post-traumatic chemosensory dysfunction was also a significant predictor (OR 2.08; p-value=0.039; 95% CI 1.04 - 4.16). Concerning psychophysical tests, we found that the probability of a patient to present weight loss increased by 8% for every 1-unit reduction in Taste Strips score (p-value=0.006; 95% CI 0.87 - 0.98). Conclusion: We recommend investigating weight loss in smell and taste consultations, especially when patients report changes in aroma perception, parosmia, duration of symptoms for less than two years, head injury, and when low Taste Strips score is measured.

Five-year Outcomes of Sleeve Gastrectomy: A Prospective Multicenter study

Background Sleeve gastrectomy (SG) is the most frequently performed bariatric procedure in the world. Our purpose was to evaluate the percentage of excess weight loss (%EWL), resolution of obesity-related comorbidities after SG, and identify predictive factors of weight loss failure. Methods A prospective cohort study of adults who underwent SG during 2014 in 7 Belgian-French centers. Their demographic, preoperative, and postoperative data were prospectively collected and analyzed statistically. Results Overall, 529 patients underwent SG, with a mean preoperative weight and body mass index (BMI) of 118.9 ± 19.9 kg and 42.9 ± 5.5 kg/m2, respectively. Body mass index significantly decreased to 32.2 kg/m2 at 5 years ( P < .001). The mean %EWL was 63.6% at 5 years. A significant reduction in dyslipidemia (28.0%-18.2%), obstructive sleep apnea (OSAS) (34.6%-25.1%), and arterial hypertension (HTN) (30.4%-21.5%) was observed after 5 years, but not for diabetes and gastroesophageal reflux disease (GERD). At multivariate analysis, age >50 years old, BMI >50 kg/m2, and previous laparoscopic adjustable gastric banding (LAGB) remained independent predictors of weight loss failure. Conclusions Five years after SG, weight loss was satisfactory; the reduction of comorbidities was significant for dyslipidemia, OSAS, and HTN, but not diabetes and GERD. Age >50 years old, BMI >50 kg/m2, and previous LAGB were independent predictors of weight loss failure.

Type 2 diabetes is an independent predictor of weight loss in Tier 3 Weight Assessment and Management Services

Introduction: A specialist weight management service provides an effective treatment option for severe obesity; however, there are limited data exploring the baseline predictors of response and effect on HbA1c following engagement with the service.Methods: We used prospective data from the regional weight management services within the Hull University Teaching Hospitals NHS Trust Tier 3 Obesity Programme. Data were available for 249 patients referred to the service. T-tests were used for univariate baseline characteristics of those with and without 5% weight loss after engagement with the service. Logistic regression analysis was used to identify independent predictors of weight loss at 12 months.Results: A total of 309 patients were referred to the Tier 3 adult weight management service, of which 249 (80.6%) participated in the programme and had at least one follow-up. The median age of the study population was 46 years (range 36–55) and consisted of 66% females with a median baseline body mass index of 44 kg/m2 (range 42–45). The prevalence of type 2 diabetes was 31%, hypertension was 35%, gastro-oesophageal reflux disease was 34% and osteoarthritis was 29%. The median baseline weight on enrolment in the programme was 126 kg (range 115–138). During the follow-up period of 1 year, the median weight fell to 120.5 kg at 3 months, 119.6 kg at 6 months, 117.7 kg at 9 months and 117.5 kg at 12 months. The median HbA1c fell from a baseline of 60.25 mmol/mol to 54.4 mmol/mol during the follow-up period. Sixty-four patients had a baseline HbA1c of >53 mmol/mol (7% HbA1c), which fell to <53 mmol/mol in 21% of patients during the follow-up period. In the logistic regression model, higher age (OR 1.05, p=0.0001), type 2 diabetes (OR 2.54, p=0.002) and dyslipidaemia (OR 2.21, p=0.03) were independently associated with more than 5% weight loss at 12 months follow-up.Conclusion: Engagement with Tier 3 adult weight management is associated with significant weight loss and improvement in glycaemic control in a large proportion of patients at one year. Higher age, diabetes and dyslipidaemia at baseline are independent predictors of weight loss on the Tier 3 weight management service.